SECTION 1. COMPANY AND MATERIAL IDENTIFICATION

Supplier of Data: Getwell Pharmaceuticals
474, Udyog Vihar, Phase-V,
Gurgaon - 122 016, Haryana, INDIA

In case of emergency call: + 91 124 4014 403 / 04

Generic names: Doxorubicin HCl liposome injection
Doxorubicin HCl [ pegylated liposomal]

Trade names: I-Dox®, Gedawell™

Date of Preparation: February 15, 2017

Note : This MSDS is written to provide health and safety information for personnel that will be handling the final product (i.e. transportation, distribution and health care workers). For health and safety information during manufacturing refer to the appropriate MSDS of each component.

SECTION 2. PRODUCT COMPOSITION

<table>
<thead>
<tr>
<th>Component</th>
<th>CAS#</th>
<th>Formula</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin Hydrochloride</td>
<td>25316-40-9</td>
<td>C_{27}H_{29}NO_{11} - HCl</td>
<td>0.2%</td>
</tr>
<tr>
<td>Liposomal carrier*</td>
<td>Not applicable</td>
<td>Not applicable</td>
<td>99.8%</td>
</tr>
</tbody>
</table>

* Contains N- ( carbamoyl-methoxypolyethelenc glycol 2000)- 1, 2- distearoyl-sn-glycero-3-phosphoethanolamine sodium salt( MPEG-DSPE), fully hydrogenated soy phosphatidylcholine(HSPC), cholesterol, ammonium sulfate, histidine, sucrose and hydrochloric acid and/or sodium hydroxide for pH control.

SECTION 3. HEALTH HAZARDS

WARNING STATEMENT

CAUTION: Contains Doxorubicin Hydrochloride an antineoplastic agent used in chemotherapy. Doxorubicin Hydrochloride is a known carcinogen in animals and a probable carcinogen in humans. This drug is intended for human pharmaceutical use by intravenous infusion as prescribed by a physician.
Section 3. Health Hazards

Precautionary statement
  Irritant
  Irritating to eyes, skin and mucosa

Potential routes to exposure
  Skin, eyes, ingestion, inhalation, accidental injection

Systemic
  Acute: Due to the nature of the use (intravenous infusion) of this drug no oral or inhalation toxicity data exists.
  Chronic: Due to the nature of the use (intravenous infusion) of this drug no oral or inhalation toxicity data exists.

Reproductive and Developmental Toxicity
  Doxorubicin HCl Liposome Injection is embryotoxic at doses of 1mg/kg/day (about 1/3 of the recommended human dose on mg/m$^2$ basis) in rats. Doxorubicin HCl Liposome Injection is embryotoxic and abortifacient at 0.5mg/kg/day (about ¼ the recommended human dose on mg/m2 basis) in rabbits. No data exists, for tests in humans, to confirm or deny the results of the animal models.

Carcinogenicity and Mutagenicity
  Although no studies have been conducted with Doxorubicin HCl Liposome Injection has been shown to have mutagenic and carcinogenic properties when tested in animal models. No data exists, for tests in humans, to confirm or deny the results of the animal models.

Permissible Exposure Limit
  No OSHA or ACGIH exposure limits have been set.

Section 4. First Aid Measures

Eye contact
  Immediately flush eyes with copious amounts of water for at least 15 minutes. If irritation develops seek medical attention.

Skin contact
  Remove contaminated clothing and wash area thoroughly with soap and water for at least 15 minutes. Thoroughly wash with soap and water any garments that might have been contaminated before using again. If irritation develops seek medical attention.
SECTION 4. FIRST AID MEASURES

Inhalation
Remove person to fresh air and notify emergency medical personnel.

Ingestion
Do not induce vomiting. Notify emergency medical personnel.

Accidental Injection
In studies with rabbits, lesions that developed after subcutaneous injection of Doxorubicin HCl Liposome Injection were minor and reversible compared to the more severe and irreversible lesions and tissue necrosis that developed after subcutaneous injection of conventional doxorubicin HCl. Clean the puncture wound to prevent infection. Follow the local procedures concerning the possible exposure to blood borne pathogens, if needle was previously used. Seek medical attention.

SECTION 5. FIRE PROTECTION

Extinguishing media
Water spray, carbon dioxide, dry chemical powder or foam

Special fire fighting procedures
Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

SECTION 6. ACCIDENTAL RELEASE MEASURES

If material is released or spilled, take proper precautions to minimize exposure by using appropriate personal protective equipment. Deny access to the spill area and minimize the spreading of the material. Be aware of broken glass. Carefully soak up any spilled material using Chemo-pads or other absorbent pads. Wipe area to remove as much of the liquid as possible. Apply bleach, or 5-6% sodium hypochlorite solution, to the affected area and let sit for at least two hours. Wipe the area down to remove the bleach and wash the area with soap and water. Collect all materials generated during the clean up in a suitable container and dispose of in accordance with the applicable local, state and federal waste disposal laws.

SECTION 7. HANDLING AND STORAGE

Avoid contact with skin, eyes and mucosa. Wash thoroughly after handling. Refrigerate at between 2º C and 8º C (36ºF and 46ºF).
SECTION 8. EXPOSURE CONTROL

Wear latex gloves suitable for handling chemotherapy agents, safety goggles or glasses with side shields and a laboratory coat. Prepare syringes in a bio-safety cabinet or fume hood. Avoid generating aerosols when priming syringes.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Translucent liquid</td>
</tr>
<tr>
<td>% Volatile</td>
<td>Not Available</td>
</tr>
<tr>
<td>Color</td>
<td>Red</td>
</tr>
<tr>
<td>Evaporation</td>
<td>Not Available</td>
</tr>
<tr>
<td>Odor</td>
<td>Unknown</td>
</tr>
<tr>
<td>Melting Point</td>
<td>Not Available</td>
</tr>
<tr>
<td>Boiling Point</td>
<td>Not Available</td>
</tr>
<tr>
<td>Solubility in water</td>
<td>Good</td>
</tr>
<tr>
<td>pH</td>
<td>6.5</td>
</tr>
<tr>
<td>Spec. Gravity</td>
<td>1.03</td>
</tr>
</tbody>
</table>

SECTION 10. STABILITY AND REACTIVITY

Stability
- Stable

Hazardous combustion or decomposition products:
- Nature of decomposition products is not known.

Hazardous Polymerization:
- Will not occur

SECTION 11. TOXICOLOGICAL INFORMATION

Acute effects
- May be harmful by inhalation and ingestion. Causes irritation to the skin, eyes and mucosa

Chronic effects
- Confirmed Carcinogenic, mutagenic and teratogenic in animal models.
- Probable Carcinogenic, mutagenic and teratogenic in humans.
- Possible adverse effects on male and female fertility have not been adequately evaluated, but it is suspected that the effects and adverse to human fertility.

RTECS data supplied is for the most abundant hazardous component of this product.
RTECS# 019295900 – Doxorubicin Hydrochloride.
Only selected RTECS data is presented here. See actual entry in RTECS for complete information.

Toxicity data
- LD₅₀: 2571 µg/Kg/2Y Intermittent intravenous –man
- TDL₀: 12mg/Kg/26W Intermittent intravenous –man
- LD₅₀: 16030 µg/Kg intraperitoneal – rat
- LD₅₀: 21800 µg/Kg subcutaneous- rat
- LD₅₀: 12510 µg/Kg intravenous -rat
<table>
<thead>
<tr>
<th>LD$_{50}$</th>
<th>Concentration</th>
<th>Route/Dose and Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>16 mg/Kg</td>
<td>intramuscular-rat</td>
<td></td>
</tr>
<tr>
<td>698 mg/Kg</td>
<td>oral-mouse</td>
<td></td>
</tr>
<tr>
<td>11160 μg/Kg</td>
<td>intraperitoneal – mouse</td>
<td></td>
</tr>
<tr>
<td>7678 μg/Kg</td>
<td>subcutaneous -mouse</td>
<td></td>
</tr>
<tr>
<td>1245 μg/Kg</td>
<td>intravenous -mouse</td>
<td></td>
</tr>
<tr>
<td>13700 μg/Kg</td>
<td>intramuscular-mouse</td>
<td></td>
</tr>
<tr>
<td>6 mg/Kg</td>
<td>intravenous –rabbit</td>
<td></td>
</tr>
</tbody>
</table>

**SECTION 11. TOXICOLOGICAL INFORMATION**

- Mutagenicity Data [RTECS]
- Carcinogenicity Data [RTECS]
- Reproductive Effects Data [RTECS]

Target organs
Bone marrow, heart, immune system, reproductive system (male)

**SECTION 12. ECOLOGICAL INFORMATION**

Data not available

**SECTION 13. DISPOSAL CONSIDERATIONS**

Mix material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Follow all local, state and federal Environmental, Health and Safety regulations.

**SECTION 14. TRANSPORTATION INFORMATION**

Doxorubicin HCl Liposome Injection is not classified as a hazardous material according to regulations of the US Department of Transportation (49 CFR 173) nor the United Nations Recommendations on the Transport of Dangerous Goods.

**SECTION 15. REGULATORY INFORMATION**

- UN number: Not listed
- RID/ADR: Not listed
- EINECS: Not listed (Doxorubicin HCl Liposome Injection is not listed. The active ingredient, doxorubicin hydrochloride, is listed as 246-818-3)
- TSCA: Not listed*
- RCRA: Not listed*
- SARA (302): Not listed*
- SARA (313): Not listed*
- OSHA: No exposure limits set*
* Neither Doxorubicin HCl Liposome Injection nor its active ingredient, doxorubicin hydrochloride, is listed.

SECTION 16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. Getwell Pharmaceuticals shall not be held liable for any damage resulting from handling or from contact with the above product. See your invoice or packing slip for any additional terms and conditions.